vs
Orchid Island Capital, Inc.（ORC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Orchid Island Capital, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.1倍（$38.5M vs $35.5M），Orchid Island Capital, Inc.净利率更高（268.7% vs -304.2%，领先573.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 372.6%），过去两年Orchid Island Capital, Inc.的营收复合增速更高（301.6% vs 60.5%）
Orchid Island Capital是一家总部设在美国的专业金融企业，以房地产投资信托的形式开展运营，主要投资机构类及非机构类住宅抵押贷款支持证券，深耕美国固定收益市场，致力于为投资者创造稳定的经风险调整后的长期回报。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ORC vs RXRX — 直观对比
营收规模更大
ORC
是对方的1.1倍
$35.5M
营收增速更快
RXRX
高出309.2%
372.6%
净利率更高
ORC
高出573.0%
-304.2%
两年增速更快
ORC
近两年复合增速
60.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.5M | $35.5M |
| 净利润 | $103.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 268.7% | -304.2% |
| 营收同比 | 372.6% | 681.7% |
| 净利润同比 | 1764.9% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORCRXRX
| Q4 25 | $38.5M | $35.5M | ||
| Q3 25 | $26.9M | $5.2M | ||
| Q2 25 | $23.2M | $19.2M | ||
| Q1 25 | $19.7M | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $340.0K | $26.1M | ||
| Q2 24 | $-697.0K | $14.4M | ||
| Q1 24 | $-2.5M | $13.8M |
净利润ORCRXRX
| Q4 25 | $103.4M | $-108.1M | ||
| Q3 25 | $72.1M | $-162.3M | ||
| Q2 25 | $-33.6M | $-171.9M | ||
| Q1 25 | $17.1M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $17.3M | $-95.8M | ||
| Q2 24 | $-5.0M | $-97.5M | ||
| Q1 24 | $19.8M | $-91.4M |
毛利率ORCRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率ORCRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率ORCRXRX
| Q4 25 | 268.7% | -304.2% | ||
| Q3 25 | 267.8% | -3135.3% | ||
| Q2 25 | -145.0% | -894.2% | ||
| Q1 25 | 86.9% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 5094.1% | -367.5% | ||
| Q2 24 | 714.3% | -676.6% | ||
| Q1 24 | -794.2% | -662.4% |
每股收益（稀释后）ORCRXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.9M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $1.4B | $1.1B |
| 总资产 | $11.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ORCRXRX
| Q4 25 | $665.9M | $743.3M | ||
| Q3 25 | $583.9M | $659.8M | ||
| Q2 25 | $440.8M | $525.1M | ||
| Q1 25 | $396.4M | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | $322.1M | $427.6M | ||
| Q2 24 | $241.0M | $474.3M | ||
| Q1 24 | $190.4M | $296.3M |
总债务ORCRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益ORCRXRX
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $912.0M | $919.1M | ||
| Q1 25 | $855.9M | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $656.0M | $524.6M | ||
| Q2 24 | $555.9M | $584.4M | ||
| Q1 24 | $481.6M | $401.2M |
总资产ORCRXRX
| Q4 25 | $11.7B | $1.5B | ||
| Q3 25 | $9.1B | $1.4B | ||
| Q2 25 | $7.6B | $1.3B | ||
| Q1 25 | $7.3B | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $5.9B | $726.5M | ||
| Q2 24 | $4.9B | $775.9M | ||
| Q1 24 | $4.2B | $557.8M |
负债/权益比ORCRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 1.16× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ORCRXRX
| Q4 25 | $120.4M | $-46.1M | ||
| Q3 25 | $28.0M | $-117.4M | ||
| Q2 25 | $18.4M | $-76.4M | ||
| Q1 25 | $25.8M | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | $-14.8M | $-59.2M | ||
| Q2 24 | $19.3M | $-82.2M | ||
| Q1 24 | $45.0M | $-102.3M |
自由现金流ORCRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率ORCRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度ORCRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率ORCRXRX
| Q4 25 | 1.16× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.86× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
